Executive Summary

The ratio of full, genome-containing adeno-associated virus (AAV) capsids to empty capsids is a key quality attribute that directly impacts the potency and manufacturability of a gene therapy candidate. High levels of empty capsids can increase the total particle dose needed for efficacy, elevating the potential for unwanted immune responses and complicating regulatory submissions. This overview details the analytical strategies for characterizing AAV preparations and the process development approaches used to mitigate empty capsid content, ensuring a consistent and well-defined product profile for global IND filings.

The Impact of Empty Capsids on AAV Program Viability

In AAV vector production, the formation of empty capsids lacking the therapeutic DNA sequence is an inherent part of the biological process. These non-functional particles are structurally similar to their genome-containing counterparts and can present significant challenges for clinical translation. An uncharacterized or high percentage of empty capsids complicates accurate dosing and can contribute to an increased immunogenic load on the patient.

Regulatory agencies globally expect a well-characterized and consistent product. A high and variable empty-to-full ratio is a common reason for clinical holds and requests for additional CMC data. Establishing robust analytical methods early is fundamental to de-risking a program.

Analytical Characterization as a Cornerstone of CMC

Defining the quality of an AAV preparation requires a suite of orthogonal analytical methods. No single technique provides a complete picture, so a multi-faceted approach is necessary to satisfy international (ICH) guidelines.

• Analytical Ultracentrifugation (AUC): Provides a definitive measure of the sedimentation properties of different particle species, allowing for precise quantification of full and empty capsids.

• Cryo-Transmission Electron Microscopy (Cryo-TEM): Offers direct visualization of particles, distinguishing between full and empty capsids based on their electron density.

• Anion-Exchange Chromatography (AEX-HPLC): Separates particles based on surface charge differences between full and empty capsids, providing a reliable method for quantification.

• Charge Detection Mass Spectrometry (CDMS): Measures the mass and charge of individual particles, offering high-resolution data on the vector population.

Understanding the vector’s fundamental biology is also informative. Research connecting the AAV2 capsid’s heparin-binding motif to T-cell activation (PMID: 16845388) underscores why minimizing non-functional particle load is a primary safety objective. Similarly, identifying the specific amino acids on the AAV9 capsid responsible for galactose binding and tissue tropism (PMID: 22514350) highlights the need for a deeply characterized product to ensure predictable in vivo performance.